MYDCOMBI
Peakphenylephrine hydrochloride; tropicamide
NDAOPHTHALMICSPRAY, METERED
Approved
May 2023
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
MYDCOMBI (phenylephrine hydrochloride; tropicamide) is tropicamide, the anticholinergic component of mydcombi, blocks the responses of the sphincter muscle of the iris, dilating the pupil (mydriasis). First approved in 2023.
Drug data last refreshed 41m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MYDCOMBI is a fixed-dose combination ophthalmic spray containing phenylephrine hydrochloride (alpha-1 adrenergic agonist) and tropicamide (anticholinergic agent) approved in May 2023. It is indicated for pupil dilation (mydriasis) during ophthalmic procedures by dual mechanism: tropicamide blocks the iris sphincter muscle while phenylephrine contracts the iris dilator muscle. The metered spray formulation represents a novel delivery approach to a well-established pharmacological indication.
Peak5.0 years to LOE
Early-stage peak phase product with no documented competitive pressure suggests opportunity for market expansion and brand team growth.
Mechanism of Action
Tropicamide, the anticholinergic component of MYDCOMBI, blocks the responses of the sphincter muscle of the iris, dilating the pupil (mydriasis). Phenylephrine hydrochloride, the alpha-1 adrenergic agonist component of MYDCOMBI, acts as a mydriatic agent by contracting the dilator muscle of the…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MYDCOMBI offers early-stage commercial career opportunities in a niche ophthalmic market with no current competition, making it attractive for professionals seeking to build franchise expertise in a defensible space. However, the zero linked jobs and lack of expansion trials suggest a modest-sized team focused on market penetration rather than pipeline advancement.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.